Figure 2.
TSLP enhances the viability and proliferation of ESCs. We incubated ESCs (n=6) (1×104 cells/well in 96-well plates for SRB assay; 1×105 cells/well in 96-well plates for flow cytometry) with recombinant human TSLP (rhTSLP) from 0.1 to 100 ng/ml or anti-human TSLP neutralizing antibody (0.25 μg/ml) (α-TSLP) for 48 h, and then the viability (A) and the expression of Ki67 (B, C) in ESCs were analyzed by SRB assay and flow cytometry. These pictures are representatives of three individual experiments. Data are expressed as the mean ± SD. P<0.05, **P<0.01 and ***P<0.001 as compared to control.